Skip to the guide
EXACT 41

Sleep research / EDUCATIONAL GUIDE

DSIP

DSIP 5 mg box packaging mockup
Packaging mockup
5 mg€29.90

Research aims, observed effects
and the limits of the evidence.

Small historical human studiesSources checked 6 September 2026

THE IDEA IN EVERYDAY TERMS

Sleep quality, tested beyond the name

DSIP stands for delta sleep-inducing peptide. Researchers have asked whether it changes sleep duration, sleep stages and waking during the night. These are measurable questions: a compound with “sleep” in its name still needs to improve sleep meaningfully when compared with an inactive placebo.

Read the background ↗

Small, short-term human sleep study

What has actually been shown?

The cited insomnia study recorded sleep objectively and compared DSIP with placebo. Some measurements changed, but several differences were not significant, and some apparent advantages were already present before treatment. The authors judged the improvement to have little clinical significance. It does not support a promise of deeper sleep, reliable insomnia relief or feeling more refreshed the next day.

Read the evidence ↗

01 / OVERVIEW

What is DSIP?

DSIP stands for delta sleep-inducing peptide, also called emideltide. Its name reflects its research history, not a guarantee that it induces sleep. [1]

02 / RESEARCH AIMS

Why it is studied.

Historical trials examined whether DSIP improved sleep in people with chronic insomnia. [1]

03 / RESEARCH MAP

Following the research question.

The clinical report assesses sleep outcomes rather than establishing a definitive receptor mechanism. A clear, validated human mechanism is not demonstrated by the source reviewed. [1]

DSIP research map: DSIP; Sleep measurements; Limited clinical significanceRESEARCH MAP / DSIP01DSIP02Sleep measurements03Limited clinical significance
Conceptual research map, not a molecular structure or a proven chain of clinical effects. [1]

04 / OBSERVED EFFECTS

What the evidence shows.

A short-term insomnia study concluded that the observed improvement had little clinical significance. This is an important counterpoint to claims based on the compound’s name. [1]

Study context

Historical human study

Key distinction

Weak clinical finding

Uncertainty

Durability unresolved

A selected-source overview, not a systematic review. Research findings are not verified effects of an independently supplied sample.

05 / SAFETY AND LIMITATIONS

Risks belong beside the findings.

FDA identifies insufficient route-specific safety information and possible immunogenicity risks. [2]

Small, older studies do not establish durable benefit or long-term safety, and cannot support predictable sleep-enhancement claims.

06 / REFERENCES

Go to the source.

  1. DSIP in chronic insomnia ↗

    Primary short-term clinical study; authors reported little clinical significance.

  2. FDA — Safety concerns for certain compounded substances ↗

    Regulatory safety assessment; route and formulation matter.